- Browse by Subject
Browsing by Subject "Pregnant"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Fluoride Metabolism in Pregnant Women: A Narrative Review of the Literature(MDPI, 2022) Castiblanco-Rubio, Gina A.; Martinez-Mier, E. Angeles; Cariology, Operative Dentistry and Dental Public Health, School of DentistryEpidemiological studies use biomarkers of fluoride exposure in pregnant women as surrogate measures of fetal fluoride exposure; however, there is little understanding of how pregnancy affects fluoride metabolism and its biomarkers. This narrative review summarizes the changes of pregnancy that have the potential to impact fluoride’s absorption, distribution and excretion, and highlights the limited body of evidence on the topic. The physiologic systems that experience pregnancy-associated changes relevant to fluoride’s metabolism are the cardiovascular, renal, metabolic and gastrointestinal, as well bone and calcium metabolism and the body’s acid-base balance. The available evidence indicates that fluoride is found in the maternal plasma and urine, placenta, amniotic fluid and fetus. Although plasma and urinary fluoride vary across gestation, there is insufficient quality evidence to determine the direction or extent of such variation. Furthermore, there is no doubt that fluoride from maternal blood crosses the placenta and is absorbed and excreted by the fetus; however, the biological mechanisms behind this placental passage are unknown. Research on maternal and prenatal biomarkers of fluoride exposure would benefit from studies on how pregnancy-associated changes affect the metabolism of fluoride across gestation, the mechanisms for the intestinal absorption of fluoride in pregnant women, and the placental passage of fluoride.Item The Health Care Encounters of Pregnant and Postpartum Women With Substance Use Disorders(2020-06) Renbarger, Kalyn Marie; Draucker, Claire Burke; Shieh, Carol; Moorman, Meg; Latham-Mintus, KenziePregnant and postpartum women with substance use disorders (SUDs) are likely to experience adverse health care encounters that contribute to poor health outcomes for them and their infants. The purpose of this dissertation is to describe the health care encounters of pregnant and postpartum women with SUDs. This dissertation includes two studies. The first study is a metasynthesis of published qualitative studies using a metasummary approach to classify the types of health care encounters experienced by pregnant and postpartum women with SUDs. A taxonomy of health care encounters was developed. Five types of adverse encounters were identified and labeled as (a) judgmental, (b) disparaging, (c) scrutinizing, (d) disempowering, and (e) deficient care. Three types of beneficial encounters were identified and labeled as (a) recovery-based, (b) accepting, and (c) effective care. The second study was a qualitative descriptive study conducted to describe factors that influence the formation of trusting relationships between maternity nurses and pregnant and postpartum women with SUDs. Interviews with 15 maternity nurses and 10 pregnant and postpartum women with SUDs were conducted. Content analysis of the participant narratives revealed a number of characteristics of maternity nurses and pregnant and postpartum women with SUDs that helped or hindered trusting relationships. Six characteristics of maternity nurses were identified and labeled as (a) rapport-building with women, (b) demeanor toward women, (c) provision of care, (d) provision of information, (e) attitude toward substance use, and (f) addiction expertise. Five characteristics of the women were identified and labeled as (a) engagement with nurses, (b) demeanor toward nurses, (c) acceptance of care, (d) investment in recovery, and (e) bonding with infant. Adverse encounters were often associated with provider stigma related to substance use during pregnancy and limited provider knowledge related to addiction. The findings will contribute to the development of strategies to improve the health care encounters of this population by promoting stigma awareness and communication skills training.Item Prenatal Substance Misuse: Exploring Healthcare Providers' Attitudes and Perceptions(2019-01) Trainor, Kristin Elise; Vernon, Robert; Adamek, Margaret E.; McCabe, Heather; Brann, MariaTo maximize beneficial outcomes for babies and mothers in substance misuse situations, it is necessary to understand the current societal factors and the stigma that healthcare providers may be imposing on the families. More than 5% of all pregnancies are affected by prenatal substance misuse prompting a public health crisis. The negative effects from drug misuse on the growing baby ranges from neonatal abstinence syndrome (NAS), mental retardation, behavioral abnormalities, and neurological deficits. The exposure also causes lengthy hospitalizations for babies and high financial costs. The provider must balance their own feelings and beliefs about substance misuse in pregnancy while simultaneously providing appropriate and supportive care to the mother. However, health-related stigma can occur as providers must care for both mother and baby, in an often stressful work environment. This research explored structural stigma, which broadly encompassed the policies and cultural practices, towards women with prenatal substance misuse among providers in a maternal/fetal healthcare unit. The study, with 117 participants from an area hospital system, examined several variables including the attitudes, perceptions, and stigma among healthcare providers towards prenatal substance misuse. A factorial MANOVA and descriptive analysis was used to assess the data. Among the findings, a significant difference was found between the type of employment discipline and a practitioner’s attitudes and level of structural sigma. Direct Care Nurses had an increased negative attitude towards women with prenatal substance misuse. Additionally, there was a strong correlation (r=0.612) between the cause of substance misuse and a healthcare provider’s attitudes towards prenatal substance misuse. If the provider believed substance misuse stemmed from a moral flaw or failing, he/she had a more negative attitude towards women with prenatal substance misuse. The current study identified the potential stigma and attitudes among healthcare providers and offered insight into the practice methods within the healthcare setting. Specifically, a three-tiered protocol to improve the culture, education, and practice within the hospital setting emerged.Item Psychiatric Co-Morbidities in Pregnant Women with Opioid Use Disorders: Prevalence, Impact, and Implications for Treatment(Springer, 2017) Arnaudo, Camila L.; Andraka-Christou, Barbara; Allgood, Kacy; Department of Psychiatry, IU School of MedicinePurpose of Review This review seeks to investigate three questions: What is the prevalence of comorbid psychiatric diagnoses among pregnant women with opioid use disorder (OUD)? How do comorbid psychiatric illnesses impact pregnant women with OUD? And how do comorbid psychiatric illnesses affect the ability of pregnant women with OUD to adhere to and complete OUD treatment? Recent Findings Based on this literature review, 25–33% of pregnant women with OUD have a psychiatric comorbidity, with depression and anxiety being especially common. However, of the 17 studies reviewed only 5 have prevalence rates of dual diagnosis in pregnant women with OUD as their primary outcome measures, their N’s were typically small, methods for determining psychiatric diagnosis were variable, and many of the studies were undertaken with women presenting for treatment which carries with its implicit selection bias. Of the women enrolled in treatment programs for SUD, those with psychiatric comorbidity were more likely to have impaired psychological and family/social functioning than those without psychiatric comorbidity. Greater severity of comorbid psychiatric illness appears to predict poorer adherence to treatment, but more research is needed to clarify this relationship with the psychiatric illness is less severe. Summary While cooccurrence of psychiatric disorders in pregnant women with opioid use disorder appears to be common, large population-based studies with validated diagnostic tools and longitudinal assessments are needed to obtain definitive rates and characteristics of cooccurring illnesses. Integrated prenatal, addiction, and psychiatric treatment in a setting that provides social support to pregnant patients with OUD is most effective in maintaining women in treatment. More research is still needed to identify optimal treatment settings, therapy modalities, and medication management for dually diagnosed pregnant women with OUD.